Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial. (Q38383351)
Jump to navigation
Jump to search
scientific article published on 19 December 2016
Language | Label | Description | Also known as |
---|---|---|---|
English | Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial. |
scientific article published on 19 December 2016 |
Statements
Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial (English)
Gregor Verhoef
Gilles Salles
Franck Morschhauser
Ralf U Trappe
Ulrich Dührsen
Marion Subklewe
Thomas Tousseyn
Ingeborg A Hauser
Corrado Tarella
Eric Van Den Neste
Olivier Gheysens
Hanno Riess
Sylvain Choquet
Daan Dierickx
Martin H Dreyling
Volker Kliem
Ioannis Anagnostopoulos
Veronique Leblond